- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Patent holdings for IPC class A61P 3/10
Total number of patents in this class: 13251
10-year publication summary
|
422
|
638
|
903
|
860
|
1013
|
1015
|
940
|
945
|
885
|
347
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Eli Lilly and Company | 4039 |
190 |
| Boehringer Ingelheim International GmbH | 4510 |
159 |
| Novo Nordisk A/S | 2302 |
128 |
| Takeda Pharmaceutical Company Limited | 2721 |
114 |
| F. Hoffmann-La Roche AG | 7839 |
108 |
| Janssen Pharmaceutica N.V. | 3234 |
108 |
| Pfizer Inc. | 3371 |
86 |
| Daiichi Sankyo Company, Limited | 1888 |
86 |
| The Regents of the University of California | 20556 |
80 |
| Sanofi | 4240 |
78 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 858 |
75 |
| Shionogi & Co., Ltd. | 863 |
71 |
| Société des Produits Nestlé S.A. | 9987 |
66 |
| Merck Sharp & Dohme LLC | 3723 |
62 |
| Sunshine Lake Pharma Co., Ltd. | 618 |
60 |
| Novartis AG | 10345 |
55 |
| The Board of Trustees of the Leland Stanford Junior University | 6592 |
54 |
| Merck Sharp & Dohme Corp. | 2184 |
50 |
| Bristol-myers Squibb Company | 4812 |
49 |
| Sanofi-Aventis Deutschland GmbH | 2605 |
49 |
| Other owners | 11523 |